Addressing the Drug Shortage Crisis

Pharma prepares for looming tariffs, as the US president signals a phased increase starting Aug. 1, but the official starting tax rate is yet to be determined.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug across 120 low- and lower-middle-income countries over the next three years.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

The Craigavon investment enhances Almac’s global clinical supply network with upgraded storage, distribution, and shipping capabilities to meet the growing demand for temperature-sensitive medicines.

Amid the push for reshoring and fiscal reform, the tariffs are part of a broader effort to rebalance trade and fund domestic initiatives, as the pharma sector awaits potential levies of its own.